PMID- 37841017
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231020
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 10
DP  - 2023
TI  - The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the 
      treatment of plaque psoriasis: a systematic review and meta-analysis of 
      randomized controlled trials.
PG  - 1264667
LID - 10.3389/fmed.2023.1264667 [doi]
LID - 1264667
AB  - BACKGROUND: Orally effective therapeutics for plaque psoriasis with improved 
      response rates, lower toxicity and costs are needed in clinical practices. This 
      study aims to assess the efficacy and safety of the recently approved TYK2 
      inhibitor deucravacitinib in adults with moderate to severe plaque psoriasis 
      through meta-analysis. METHODS: A systematic search was performed for eligible 
      studies using electronic databases, including PubMed, Embase, Cochrane Library, 
      Clinical Trials, the EU Clinical Trials Register, and the International Clinical 
      Trials Registry Platform (ICTRP). Randomized controlled trials (RCTs) comparing 
      the efficacy and safety of deucravacitinib vs. placebo or active comparators in 
      adult patients with plaque psoriasis were included. The effectiveness of 
      deucravacitinib was evaluated using a 75% improvement in Psoriasis Area and 
      Severity Index (PASI 75) from baseline and the proportion of patients achieving 
      the static Physician's Global Assessment (sPGA) response. The secondary endpoint 
      was the proportion of patients achieving PASI 90, PASI 100, ssPGA 0/1, and 
      Dermatology Life Quality Index 0/1 (DLQI). The incidence of adverse events (AEs), 
      serious AEs (SAEs), and AE-related treatment discontinuation were statistically 
      analyzed to determine the safety of deucravacitinib. RESULTS: The systematic 
      review and meta-analysis included five RCTs involving 2,198 patients with 
      moderate to severe plaque psoriasis. Results showed that deucravacitinib was 
      superior to placebo as well as active comparator apremilast in multiple key 
      endpoints, including PASI 75, sPGA 0/1, PASI 90, PASI 100, DLQI 0/1 at week 16. 
      Moreover, a durable response was seen in the two 52-week studies. Safety 
      assessment showed that deucravacitinib was generally well tolerated, and the 
      incidence of AEs, SAEs, and AE-related treatment discontinuation was low and 
      balanced across groups. CONCLUSION: Deucravacitinib demonstrated superior 
      efficacy to apremilast in adult patients with moderate to severe plaque psoriasis 
      with an acceptable safety profile and has the potential to be used as the 
      first-line oral therapy for plaque psoriasis.
CI  - Copyright (c) 2023 Qiu, Liu, Liu, Lin and Shi.
FAU - Qiu, Jingyue
AU  - Qiu J
AD  - Pharmaceutical Department, PLA Strategic Support Force Medical Center, Beijing, 
      China.
FAU - Liu, Jiakuo
AU  - Liu J
AD  - Pharmaceutical Department, PLA Strategic Support Force Medical Center, Beijing, 
      China.
FAU - Liu, Wenwen
AU  - Liu W
AD  - Shandong Provincial Center for ADR Monitoring, Jinan, China.
FAU - Lin, Fei
AU  - Lin F
AD  - Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, 
      Chengdu, China.
AD  - Clinical Medical College, Chengdu Medical College, Chengdu, China.
FAU - Shi, Ning
AU  - Shi N
AD  - Pharmaceutical Department, PLA Strategic Support Force Medical Center, Beijing, 
      China.
LA  - eng
PT  - Systematic Review
DEP - 20230929
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC10570425
OTO - NOTNLM
OT  - TYK2 inhibitor
OT  - autoimmune disease
OT  - deucravacitinib
OT  - meta-analysis
OT  - psoriasis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/10/16 06:48
MHDA- 2023/10/16 06:49
PMCR- 2023/09/29
CRDT- 2023/10/16 04:26
PHST- 2023/08/29 00:00 [received]
PHST- 2023/09/15 00:00 [accepted]
PHST- 2023/10/16 06:49 [medline]
PHST- 2023/10/16 06:48 [pubmed]
PHST- 2023/10/16 04:26 [entrez]
PHST- 2023/09/29 00:00 [pmc-release]
AID - 10.3389/fmed.2023.1264667 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2023 Sep 29;10:1264667. doi: 10.3389/fmed.2023.1264667. 
      eCollection 2023.